News from CRG
A public-private consortium led by the biotech Iproteos - based at the Parc Científic de Barcelona (PCB)– with the participation of the Biomedical Research Institute of Barcelona (IIBB) of the CSIC and the CRG, has launched a project to validate a new family of compounds for the treatment of vascular accumulation of cholesterol associated with atherosclerosis. The project has just received an endowment for 700,000 Euros from the Ministry of Economy, Industry and Competitiveness.
The final objective of the project is the validation of a new family of peptidomimetic compounds (derived from peptides with optimized properties) that are candidates for drugs for the treatment of vascular accumulation of cholesterol associated with atherosclerosis. Hand in hand with the efficacy trials, pharmacokinetic and pharmacodynamic bioavailability studies will also be carried out, which will provide vital information for the project to reach clinical phases.
Members of the consortium expect the results of this project to be the validation of a first-in-class drug candidate for the treatment of atherosclerosis, including a detailed study of its mechanism of action. This will subsequently enable the implementation of regulatory preclinical trials and, and will later on lead to the first administration of the candidate drug in humans.